Peer-reviewed literature
Key clinical and pharmacometric publications on inpegsomatropin (Pegpesen®): Phase II PK/PD, Phase III efficacy, and population modeling for dosing strategies.
Phase II — PK, PD & 12-week growth
Liang Y, Zhang C, Wei H, Du H, Zhang G, Yang Y, Zhang H, Gong H, Li P, Song F, Xu Z, He R, Zhou W, Zheng H, Sun L, Luo X. The pharmacokinetic and pharmacodynamic properties and short-term outcome of a novel once-weekly PEGylated recombinant human growth hormone for children with growth hormone deficiency. Front Endocrinol (Lausanne). 2022;13:922304.
DOI: 10.3389/fendo.2022.922304 · NCT04513171
Open Phase II topic Download PDF
Featured topic: Population PK/PD dosing optimization — summarized tables, timelines, limitations, and a bundled PDF of the Journal of Endocrinological Investigation (2026) modeling paper.
Population PK / PD (dosing science)
Zhao Y, Zou F, Gu J, He R, Yin Y. Optimization of dosing regimens for the long-acting growth hormone pegpesen: A population PK/PD modeling approach. J Endocrinol Invest (2026) 49:599–607. Online 5 Nov 2025.
DOI: 10.1007/s40618-025-02749-4
Pediatric GHD Phase III (efficacy & safety)
Liang Y, Wei H, Yang F, Zhang H, Chen L, Yao H, Luo X, Cheng X, Yang Y, Lian Q, Du H, Li T, Li P, Zhang G, Song F, Liang L, Liu D, Zhu S, Gong H, Gong C, Cheng X, Xu Z, Ma Y, Su Z, Zhou W, He R, Yin Y, Sun L, Luo X. A Novel Y-Shaped Pegylated Recombinant Human Growth Hormone for Children With Growth Hormone Deficiency. The Journal of Clinical Endocrinology & Metabolism. 2024; advance access 28 November 2024.
Download PDF (local copy) Publisher page
The PDF in docs/phase3-jcem-2024.pdf mirrors the long-filename
original in the project root; update both if you replace the file.